Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: Results of a pilot study

Nephrology Dialysis Transplantation

Volumn 22, Issue 11, 2007, Pages 3196-3201

  Ballarin, José ^a,b   Poveda, Rafael ^a   Ara, Jordi ^a   Pérez, Laureà ^a   Calero, Francesca ^a   Grinyó, Josep M ^a   Romero, Ramón ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Association; Membranous nephropathy; Mycophenolate mofetil; Steroids; Tacrolimus; Treatment

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROTEINURIA; REMISSION; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; ALBUMINURIA; BIOPSY; CHOLESTEROL; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROTEINURIA; TACROLIMUS;

EID: 36749085443     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm366     Document Type: Article

References (49)

1. Noel LH, Zanetti M, Droz D, Barbanel C. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979; 66: 82-89
2. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003; 23: 324-332
3. Donadio JV, Torres VE, Velosa JA et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988; 33: 708-715
4. Schiepatti A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89
5. Zucchelli P, Ponticelli C, Cagnoli L, Passerini P. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplan 1987; 2: 73-78
6. Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis 1998; 31: 1-11
7. Marx BE, Marx M. Prognosis of idiopathic membranous nephropathy: a methodologic meta-analysis. Kidney Int 1997; 51: 873-879
8. Hogan S, Muller K, Jennette C, Falk R. A review of therapeutic studies of idiopathic membranous nephropathy. Am J Kidney Dis 1995; 25: 862-875
9. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A metaanalysis of the controlled trials. J Am Soc Nephrol 1995; 5: 1553-1558
10. Perna A, Schieppatti A, Zamora J et al. Immunossuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 2004; 44: 385-401
11. Falk RJ, Hogan SL, Muller KE et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. Ann Intern Med 1992; 116: 438-445
12. Ponticelli C, Zucchelli P, Passerini IP et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604
13. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Quart J Med 1994; 87: 223-229
14. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Membranous nephropathy study group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004; 19: 1142-1148
15. Branten AJW, Reichert LJM, Koene RAP, Wetzels JFM. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Quart J Med 1998; 91: 359-366
16. Torres A, Domínguez-Gil B, Carreño A et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002; 61: 219-227
17. Guasch A, Suranyi M, Newton L et al. Short term responsiveness of membranous glomerulopathy to cyclosporine. Am J Kidney Dis 1992; 20: 472-481
18. Rostoker G, Belghiti D, Ben Maadi A, Remy P, Weil B, Lagrue G. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephrology 1993; 63: 335-341
19. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995; 47: 1130-1135
20. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1493
21. Goumenos DS, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis JG. The remission of nephrotic syndrome with cyclosporine treatment does not attenuate the progression of idiopathic membranous nephropathy. Clin Nephrol 2004; 61: 17-24
22. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br Med J 1999; 318: 1104-1107
23. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 2003; 18 [Suppl. 1]: 7-11
24. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18: 379-384
25. Artz MA, Boots JMM, Ligtenberg G et al. Conversion from Cyclosporine to Tacrolimus improves quality of life indices, renal graft function and cardiovascular risk profile. Am J Transplantation 2004; 4: 937-945
26. Kobayashi M, Muro K, Yoh K et al. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats. Nephrol Dial Transplant 1998; 13: 2501-2508
27. Szeto CC, Leung CB, Lai FM, Li PKT. Tacrolimus in resistant primary membranous nephropathy- a report of three cases. Clin Nephrol 2003; 59: 293-296
28. Srinivas TR, Kaplan B, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 2005; 80 [Suppl. 2]: S211-S220
29. Ciancio G, Miller J, Gonwa TA. Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 2005; 80 [Suppl. 2]: S191-S200
30. Lang P, Pardon A, Audard V. Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation 2005; 79 [Suppl. 3]: S47-S48
31. Maes BD, Oyen R, Claes K et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842-1849
32. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114
33. Hauser IA, Sterzel RB. Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease. Curr Opin Nephrol Hypertens 1999; 8: 1-6
34. Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003; 18: 1233-1234
35. Miller G, Zimmerman R,III, Radhakrishnan J et al. Use of Mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250-256
36. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774
37. Sepe V, Rossi N, Adamo G, Dal Canton A. Mycophenolate mofetil in IgA nephropathy. Kidney Int 2004; 66: 1713
38. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80 [Suppl. 2]: S265-S271
39. Ziswiler R, Steinmann-Niggli K, Kappeler A et al. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 1098-1114
40. Ahsan N, Fitzsimmons WE et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245-250
41. Thomson AW. FK506. How much potential. Immunol Today 1989; 10: 6-9
42. Atcheson BA, Taylor PJ, Kirkpatrick CM et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004; 26: 284-286
43. du Buf-Vereijken PWG, Branten AJW, Wetzels JFM. Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. Am J Kidney Dis 2005; 46: 1012-1029
44. Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol 2003; 23: 355-361
45. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 1992; 42: 960-966
46. Cattran D, Pei Y, Greenwood C et al. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 1997; 51: 901-907
47. Praga M. Therapeutic measures in proteinuric nephropathy. Kidney Int 2005; 68 [Suppl. 99]: S142-S151
48. Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
49. Knight A, Askling J, Granath F, Sparen P, Ekbon A. Urinary bladder cancer in Wegener's granulomatosis: risk and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 1307-1311